We are leaders in
Combination
Immuno-oncology
ImmVirX is a clinical stage oncology company developing novel oncolytic viruses to create powerful cancer immunotherapy combinations.
What we are up to
ImmVirX is actively progressing its novel immuno-oncology agents in the clinic, targeting some of the most prevalent cancer types where patients have limited treatment options.
Our novel oncolytic immunotherapy harnesses the power of viruses to preferentially infect and kill cancer cells and induce systemic anti-tumour immune responses.
The proprietary bio-selected RNA viruses target specific receptor proteins highly expressed on a range of cancer cell types, allowing them to selectively enter, replicate in, and destroy tumour cells while creating beneficial changes in the tumour micro-environment, potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.
In this way, our viral candidates are intended to increase the effectiveness of current immunotherapies, primarily immune checkpoint inhibitors and CAR-T cell therapies, in fighting cancers of high unmet need including colorectal, gastric, hepatocellular and ovarian cancer.
In the News
View our recent news stories
Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.
View All Stories
On Twitter
ImmVirX hosted an investor/clinician presentation event at Western Sydney University.
Our CEO Dr Malcolm McColl & CSO Prof Darren Shafren presented on our lead drug candidate IVX037, including promising Phase 1 Data, next steps, site expansion plans & upcoming catalysts.
